Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:6/3/2010

RICHMOND, Calif., June 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, and Ward Wolff, executive vice president and CFO, will provide an update on the progress of Sangamo's ZFP Therapeutic™ development programs and an overview of the company's business strategy at two investor conferences during the month of June:

  • The Jefferies 2010 Global Life Sciences Conference, at 9:00 am ET on Tuesday, June 8.
  • The 9th Annual Needham Healthcare Conference in New York City, at 10:40 am ET on Thursday, June 10.

Live webcasts of the presentations will be available on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. A replay of each presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic™ development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
2. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
4. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
5. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
6. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
7. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
8. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
9. Sangamo Announces Pricing of Public Offering of Common Stock
10. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
11. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... Franz Inc ., ... development tools, and market leader for Semantic Graph Database technology, today ... within the most effective system for developing and deploying applications to solve the ...
(Date:4/25/2017)... GREENVILLE, SC (PRWEB) , ... April 25, 2017 ... ... SC-based Piedmont Physical Medicine & Rehabilitation, P.A. , proudly announced today that ... will officially commence his duties on May 15, 2017. , Dr. Terzella completed ...
(Date:4/24/2017)... ... April 24, 2017 , ... It is well established that ... the broad application of this cellular target engagement concept to drug discovery has ... thermal stabilization assays are valuable methods for particular applications, but they can require ...
(Date:4/21/2017)... ... April 21, 2017 , ... Having worked on the design of ... pleased to introduce it to top lab design architects from around the country at ... VP of Industrial Design and Engineering Greg Casey will be at the show, where ...
Breaking Biology Technology:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/23/2017)... , Mar. 23, 2017 Research and Markets ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 8.8% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/20/2017)... At this year,s CeBIT Chancellor Dr. Angela Merkel ... came to the DERMALOG stand together with the Japanese Prime Minster Shinzo ... At the largest German biometrics company the two government leaders could see ... as well as DERMALOGĀ“s multi-biometrics system.   Continue ... ...
Breaking Biology News(10 mins):